<DOC>
	<DOCNO>NCT01245959</DOCNO>
	<brief_summary>The purpose study compare induction chemotherapy ( docetaxel+cisplatin+fluorouracil ) plus concurrent chemoradiotherapy concurrent chemoradiotherapy patient locoregionally advanced nasopharyngeal carcinoma ( NPC ) , order confirm value induction chemotherapy NPC patient .</brief_summary>
	<brief_title>Induction Chemotherapy Patients With Locoregionally Advanced Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>Patients present non-keratinizing NPC stage T3-4N1M0/TxN2-3M0 randomly assign receive induction chemotherapy ( docetaxel+cisplatin+fluorouracil ) plus concurrent chemoradiotherapy ( investigational arm ) concurrent chemoradiotherapy ( control arm ) . Patients arm receive radical radiotherapy , cisplatin ( 100mg/m2 ) every three week three cycle radiotherapy . Patients investigational arm receive docetaxel ( 60mg/m2 day 1 ) , cisplatin ( 60mg/m2 day 1 ) fluorouracil ( 600mg/m2 Days 1 5 ) every three week three cycle radiotherapy . Patients stratify accord treatment center stage . The primary end point failure-free survival ( FFS ) . Secondary end point include overall survival ( OS ) , distant failure-free survival ( D-FFS ) , locoregional failure-free survival ( LR-FFS ) , initial response rate treatment toxic effect . All efficacy analysis conduct intention-to-treat population ; safety population include patient receive randomly assign treatment .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Patients newly histologically confirm nonkeratinizing ( accord World Health Organization ( WHO ) histologically type ) . Tumor stag T34N1/N23 ( accord 7th American Joint Commission Cancer edition ) . No evidence distant metastasis ( M0 ) . Satisfactory performance status : Karnofsky scale ( KPS ) &gt; 70 . Adequate marrow : leucocyte count ≥4000/μL , hemoglobin ≥90g/L platelet count ≥100000/μL . Normal liver function test : Alanine Aminotransferase ( ALT ) 、Aspartate Aminotransferase ( AST ) &lt; 1.5×upper limit normal ( ULN ) concomitant alkaline phosphatase ( ALP ) ≤2.5×ULN , bilirubin ≤ULN . Adequate renal function : creatinine clearance ≥60 ml/min . Patients must inform investigational nature study give write informed consent . WHO Type keratinize squamous cell carcinoma basaloid squamous cell carcinoma . Age ≥60 year &lt; 18 year . Treatment palliative intent . Prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer . Pregnancy lactation . History previous radiotherapy ( except nonmelanomatous skin cancer outside intend RT treatment volume ) . Prior chemotherapy surgery ( except diagnostic ) primary tumor node . Any severe intercurrent disease , may bring unacceptable risk affect compliance trial , example , unstable cardiac disease require treatment , renal disease , chronic hepatitis , diabetes poor control ( fast plasma glucose &gt; 1.5×ULN ) , emotional disturbance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Nasopharyngeal carcinoma</keyword>
	<keyword>Concurrent chemoradiotherapy</keyword>
	<keyword>Induction chemotherapy</keyword>
	<keyword>Clinical trial</keyword>
</DOC>